Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON TrialC. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al.|Clinical Cancer Research|2022Cited by 74
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC. Mircea S. Tesileanu, Pim J. French, Martin J. van den Bent et al.|Neuro-Oncology|2021Cited by 66
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC. Mircea S. Tesileanu, Pim J. French, Wies Vallentgoed et al.|Acta Neuropathologica|2021Cited by 60
Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al.|Journal of Clinical Oncology|2016Cited by 34
PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletionMartin J. van den Bent, Pim J. French, Sara Erridge et al.|Neuro-Oncology|2019Cited by 29